cco-lung-fellows-thatcher-lo-鱗癌(編輯修改稿)
2024-10-03 10:09 本頁面
【文章內(nèi)容簡介】 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 Mos OS (%) N + G/C Censored pts G/C Censored pts N + G/C (n = 545) G/C (n = 548) HR: (95% CI: 。 P = .01) Median OS, Mos (95% CI) () () 1Yr OS, % (95% CI) 48 (4352) 43 (3947) 2Yr OS, % (95% CI) 20 (1624) 17 (1320) 第五頁，共十四頁。 Necitumumab + Gemcitabine/ Cisplatin, n/Events Gemcitabine/ Cisplatin, n/Events HR (95% CI) Age group, yrs 65 ≥ 65 to 70 ≥ 70 332/258 105/79 108/81 340/277 111/94 97/71 () () () Sex Women Men 95/77 450/341 90/72 458/370 () () Race White Nonwhite 457/355 88/63 456/369 92/73 () () Smoking status Never/light exsmoker Current smoker 44/34 500/383 53/44 495/398 () () ECOG PS 0 1 2 164/117 332/260 49/41 180/139 320/261 47/42 () () () Overall ITT population 545/418 548/442 () SQUIRE: OS by Subgroup Slide credit: 1 Favors necitumumab plus gem/cisplatin Favors gem/cisplatin Thatcher N, et al. Lancet Oncol. 2024。16:763774. 第六頁，共十四頁。 SQUIRE: PFS ? PFS significantly improved with necitumumab + gemcitabine/cisplatin vs gemcitabine/cisplatin alone – Median TTF: vs mos, respectively (P = .006) Thatcher N, et al. Lancet Oncol. 2024。16:763774. Slide credit: HR: (95% CI: 。 P = .02) Median PFS, Mos (95% CI) () () 3Mo PFS, % (95% CI) 79 (7683) 73 (6876) 6Mo PFS, % (95% CI) 45 (4049) 37 (3342) N + G/C (n = 545) G/C (n = 548) 0 20 40 60 80 100 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Mos PFS (%) N + G/C Censored pts G/C Censored pts 第七頁
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號-1